Literature DB >> 14523910

Oligonucleotide-based knockdown technologies: antisense versus RNA interference.

Tatjana V Achenbach1, Bodo Brunner, Kathrin Heermeier.   

Abstract

The postgenomic era is characterized by an almost intimidating amount of information regarding the sequences and expression of previously unknown genes. In response, researchers have developed an increasing interest in functional studies. At the start of such a study, one may have little more than sequence information and bioinformatic annotation. The next step is to hypothesize a potential role in the context of a cell. Testing of the hypothesis needs to be fast, cheap, and applicable to a large number of genes. Knockdown methods that rely on binding of antisense oligonucleotides to mRNA combined with a subsequent functional assay in cell culture fulfil these requirements: sequence information is sufficient for synthesis of active inhibitors. Depending on the in vitro model chosen, knockdown of gene expression can be achieved with medium or even high throughput. The two most popular methods of knockdown in cell culture are the use of antisense oligonucleotides that rely on ribonuclease H (RNAse H)-dependent cleavage of mRNA, and RNA interference triggered by small double-stranded RNA molecules. Both methods act in a sequence-specific manner and can give efficient knockdown. In both cases, researchers struggle with nonspecific "off-target" effects and the difficulty of site selection. Studies that compare the methods differ in their judgment as to which method is superior.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523910     DOI: 10.1002/cbic.200300708

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  21 in total

1.  Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation.

Authors:  Hironobu Takahashi; Yuwei Wang; David W Grainger
Journal:  J Control Release       Date:  2010-08-19       Impact factor: 9.776

2.  Use of recombinant calpain-2 siRNA adenovirus to assess calpain-2 modulation of lung endothelial cell migration and proliferation.

Authors:  Kai Qiu; Yunchao Su; Edward R Block
Journal:  Mol Cell Biochem       Date:  2006-05-30       Impact factor: 3.396

Review 3.  TRP channels as candidates for hearing and balance abnormalities in vertebrates.

Authors:  Math P Cuajungco; Christian Grimm; Stefan Heller
Journal:  Biochim Biophys Acta       Date:  2007-01-17

Review 4.  Cell culture systems for studies of bone and tooth mineralization.

Authors:  Adele L Boskey; Rani Roy
Journal:  Chem Rev       Date:  2008-09-19       Impact factor: 60.622

Review 5.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

6.  Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion.

Authors:  Sophie Iochmann; Claire Bléchet; Valérie Chabot; Annabelle Saulnier; Aniça Amini; Guillaume Gaud; Yves Gruel; Pascale Reverdiau
Journal:  Clin Exp Metastasis       Date:  2009-03-07       Impact factor: 5.150

Review 7.  Light activation as a method of regulating and studying gene expression.

Authors:  Alexander Deiters
Journal:  Curr Opin Chem Biol       Date:  2009-10-24       Impact factor: 8.822

Review 8.  Design and application of multifunctional DNA nanocarriers for therapeutic delivery.

Authors:  P Charoenphol; H Bermudez
Journal:  Acta Biomater       Date:  2013-07-27       Impact factor: 8.947

9.  Principles and applications of the photochemical control of cellular processes.

Authors:  Alexander Deiters
Journal:  Chembiochem       Date:  2010-01-04       Impact factor: 3.164

10.  Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials.

Authors:  Yuwei Wang; Kenny K Tran; Hong Shen; David W Grainger
Journal:  Biomaterials       Date:  2012-09-03       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.